First Circuit Offers Some FCA Clarity to Clinical Labratories

Clinical laboratories have long occupied an awkward position in Medicare billing. Physicians decide which tests their patients need, laboratories perform those tests, and then laboratories may be expected to defend the medical necessity of decisions they did not make. It is a little like asking the restaurant dishwasher to explain why a customer ordered the lobster.

The United States Court of Appeals for the First Circuit confronted that problem in United States ex rel. Omni Healthcare Inc. v. MD Spine Solutions LLC, 160 F.4th 248 (1st Cir. 2025). The court held that, in a False Claims Act case based on allegedly unnecessary laboratory testing, a clinical laboratory may generally rely on a physician’s order as evidence that the test was reasonable and necessary.

That is meaningful FCA clarity for clinical laboratories, but it is not a permission slip to turn off the compliance department, shred the requisition forms, and place a potted fern in the compliance officer’s chair. The protection depends on good-faith reliance. Evidence that a laboratory manipulated orders, misled physicians, ignored coverage restrictions, or deliberately avoided obvious warning signs could produce a very different result.

Why the First Circuit’s FCA Decision Matters

The False Claims Act is one of the federal government’s most powerful civil fraud enforcement tools. It creates liability for a person who knowingly presents, or causes another person to present, a false or fraudulent claim for government payment. Private whistleblowers, known as relators, may bring qui tam lawsuits on the government’s behalf and potentially receive part of a successful recovery.

Healthcare remains a major source of FCA investigations because Medicare, Medicaid, and other federal programs process an enormous number of claims under complicated coverage rules. Clinical laboratories face particular exposure involving medical necessity, billing codes, test panels, standing orders, referral relationships, marketing practices, and documentation.

The First Circuit’s decision matters because it draws a practical line between clinical decision-making and laboratory operations. A laboratory is responsible for performing and billing a test correctly. It ordinarily is not responsible for practicing medicine from the billing office and independently diagnosing the patient before honoring a licensed provider’s order.

How the OMNI Healthcare Dispute Began

MD Spine Solutions, doing business as MD Labs, was an independent clinical laboratory based in Nevada. In 2017, it began offering polymerase chain reaction testing for urinary tract infections. PCR testing can identify genetic material associated with pathogens and may produce results faster than a traditional bacterial urine culture. It can also be considerably more expensive.

OMNI Healthcare, a Florida medical practice, sent MD Labs nearly 600 requisition forms and patient samples between 2017 and 2019. MD Labs performed the requested UTI tests, returned the results, and submitted at least some claims to Medicare.

The unusual part of the story was what happened inside OMNI. According to the appellate record, OMNI’s physician-owner instructed medical assistants to order PCR tests from MD Labs even when treating providers had requested traditional cultures. He later acknowledged that he wanted to strengthen a possible Medicare fraud case against the laboratory. There was no evidence that MD Labs knew about this internal strategy. From the laboratory’s perspective, it was receiving test orders from a medical practice.

OMNI eventually filed an FCA lawsuit alleging, among other theories, that MD Labs knowingly billed Medicare for medically unnecessary PCR testing. OMNI argued that bacterial cultures were less expensive and offered comparable clinical value, making the higher-cost PCR tests unnecessary.

The federal district court granted summary judgment to MD Labs. It found insufficient evidence that the laboratory knowingly submitted false claims. The First Circuit unanimously affirmed that result.

The Legal Ingredients: Falsity, Medical Necessity, and Scienter

Medicare’s “Reasonable and Necessary” Requirement

Medicare generally excludes payment for items and services that are not reasonable and necessary for diagnosing or treating an illness or injury. CMS may address coverage through national coverage determinations, while Medicare Administrative Contractors may issue local coverage determinations. When no directly applicable national or local policy exists, coverage may be decided case by case.

In the OMNI case, the parties had no controlling national or local coverage determination that categorically prohibited the disputed PCR testing. That absence did not automatically establish coverage, but it weakened the claim that MD Labs had ignored a clear Medicare rule.

What “Knowingly” Means Under the FCA

An incorrect claim is not automatically a knowing false claim. The FCA recognizes three forms of knowledge:

• Actual knowledge that the relevant information is false;
• Deliberate ignorance of its truth or falsity; or
• Reckless disregard of its truth or falsity.

Specific intent to defraud is not required. Nevertheless, the plaintiff must produce evidence about the defendant’s state of mind. An innocent mistake, an ordinary billing dispute, or a reasonable clinical disagreement does not become fraud merely because someone later highlights it in an angry PowerPoint presentation.

The First Circuit applied the Supreme Court’s decision in United States ex rel. Schutte v. SuperValu Inc. That decision explains that FCA scienter focuses on what the defendant actually knew or believed when the claim was submitted. A court does not simply ask what a hypothetical reasonable company might have believed or what became clear years later.

What the First Circuit Actually Held

A Physician Order Generally Supports Medical Necessity

The First Circuit held that a clinical laboratory may generally rely on a physician’s test order to demonstrate that the service was reasonable and necessary. Physicians examine patients, consider symptoms, select diagnostic strategies, and make treatment decisions. Laboratory technicians process the tests those providers request.

HHS-OIG guidance recognizes this division of responsibility. Laboratories do not treat patients and generally cannot make individualized medical necessity decisions. They still have a duty not to submit false claims, but neither Medicare law nor laboratory regulations ordinarily require them to conduct a separate clinical examination before processing every order.

The court reasoned that a contrary rule could create dangerous operational incentives. Laboratories might delay testing while second-guessing physicians, refuse medically appropriate services because a less expensive option exists, or substitute a different test simply to reduce litigation risk. None of those outcomes would be especially comforting to a patient waiting for a diagnosis.

The Order Creates an Evidentiary Safe Harbor, Not Immunity

The court described a physician’s order as generally providing a safe harbor of medical necessity at the summary judgment stage. Once the laboratory shows that it performed testing pursuant to a provider’s order, an FCA plaintiff must produce evidence that rebuts, discredits, or undermines the laboratory’s reliance.

This is best understood as an evidentiary principle, not a statutory safe harbor and certainly not blanket immunity. A requisition form is powerful evidence, but it is not an enchanted shield capable of repelling every fraud allegation.

A relator may overcome the laboratory’s reliance by showing that the laboratory knew the order was unreliable, caused the provider to order unnecessary services, concealed material information, or consciously disregarded a substantial risk that the claim was false.

The Court Did Not Decide Every Medical-Necessity Question

The First Circuit affirmed because OMNI failed to produce sufficient evidence of scienter. It did not need to decide whether every PCR test was objectively medically necessary. It also did not announce that a physician’s signature automatically proves coverage in every future case.

That distinction is essential. The decision concerns whether MD Labs knowingly submitted false claims on the record before the court. It should not be summarized as “all physician-ordered testing is reimbursable,” because that would convert a carefully limited ruling into legal fan fiction.

Why OMNI’s Evidence Was Not Enough

OMNI relied on four general categories of evidence: internal emails, medical literature, the absence of Medicare coverage guidance, and allegations that MD Labs bundled multiple pathogen tests into broad panels. The First Circuit concluded that none created a genuine factual dispute about MD Labs’ knowledge.

Internal Emails

MD Labs executives had discussed contacting a Medicare contractor for medical-necessity guidance. They did not follow through before continuing to offer PCR testing. OMNI characterized the exchange as evidence that the executives recognized a serious coverage risk.

The court disagreed. Considering the full exchange, it did not demonstrate that the executives believed the claims were false or consciously disregarded a substantial and unjustifiable risk. MD Labs also consulted an infectious disease physician who supported the clinical importance of the tests.

The lesson is not that internal emails are harmless. Poorly worded messages have launched more legal headaches than anyone cares to count. The lesson is that uncertainty, curiosity, or discussion of possible guidance does not by itself establish fraudulent knowledge.

Medical Literature

OMNI cited literature questioning the value of PCR testing compared with traditional cultures. Much of it did not establish what MD Labs believed when the relevant claims were submitted. Some materials postdated the claims, while others did not directly address the particular testing decisions at issue.

Scientific disagreement can inform an FCA case, but the plaintiff must connect the literature to the defendant’s contemporaneous knowledge. Dropping a stack of journal articles onto counsel’s table is not a substitute for proving that decision-makers read, understood, and consciously ignored them.

No Controlling NCD or LCD

OMNI argued that the lack of an applicable national or local coverage determination should have caused MD Labs to question reimbursement. The court rejected that theory. Medicare frequently handles services through case-by-case adjudication when no controlling coverage policy exists.

Silence is not the same as prohibition. At the same time, laboratories should not treat regulatory silence as automatic approval. They must still review statutes, regulations, contractor articles, billing manuals, coding instructions, and other authoritative guidance.

Bundled Testing Panels

OMNI also alleged that MD Labs used requisition forms offering panels containing as many as 17 or 19 pathogen targets. Broad, preconfigured panels can create FCA risk when a laboratory knows components are unnecessary or designs forms to pressure physicians into ordering services they did not intend to request.

In this case, however, MD Labs submitted expert evidence that the tested pathogens were reasonable and within ranges supported by medical literature. OMNI did not counter with evidence of comparable quality. Arguments in a legal brief could not replace expert testimony or other admissible proof.

When Reliance on a Physician Order May Fail

The OMNI decision identifies a practical boundary. A laboratory may generally trust a legitimate physician order unless countervailing facts make that trust unreasonable or dishonest. Potential warning signs include:

• Prechecked requisition forms that automatically add expensive tests;
• Marketing materials that exaggerate a test’s accuracy, speed, or clinical value;
• Instructions to alter a provider’s selected test without obtaining approval;
• Large, unexplained changes in ordering volume or nearly identical panels for every patient;
• Complaints from physicians who did not understand what they ordered;
• Internal analyses concluding that services are not covered or medically justified;
• Ignored CMS, OIG, or Medicare contractor warnings;
• Financial relationships that may improperly influence referrals; and
• Repeated claim denials identifying the same coverage defect.

When those red flags appear, continuing to submit claims without investigation may support deliberate-ignorance or reckless-disregard allegations. A compliance program must therefore do more than collect signatures. It should examine how the orders were generated, marketed, documented, processed, coded, and billed.

Practical FCA Compliance Steps for Clinical Laboratories

Preserve Complete Ordering Records

Laboratories should retain the original order, relevant diagnosis information, provider identity, test selections, changes to the order, and communications authorizing those changes. Audit logs should show who modified an electronic requisition and when.

Review Requisition Forms for Neutrality

Forms should present test options clearly. Broad panels should not be preselected merely because they produce higher reimbursement. Physicians should be able to order narrower testing when clinically appropriate, and panel components should be transparent.

Monitor Ordering Patterns

Data analytics can identify sudden spikes, repeated high-cost panels, unusually frequent testing, duplicate services, and providers whose ordering behavior differs sharply from their peers. An alert is not proof of misconduct, but it is an invitation to ask questions before the government asks them with a subpoena.

Document Coverage Analysis

Compliance personnel should track applicable NCDs, LCDs, billing articles, contractor publications, coding changes, and claim-denial trends. When guidance is unclear, the laboratory should document its research, clinical consultation, legal advice, and reasoning.

Escalate Red Flags Promptly

A written escalation procedure should identify who reviews questionable orders, who contacts the provider, when billing must be paused, and how the resolution is recorded. Problems discovered after payment may also trigger overpayment investigation and repayment obligations.

What the Decision Means Beyond the First Circuit

The decision is binding on federal courts within the First Circuit, which covers Maine, Massachusetts, New Hampshire, Puerto Rico, and Rhode Island. Courts elsewhere are not required to follow it, although they may find its reasoning persuasive.

The ruling aligns with the practical view that ordering providers ordinarily make medical-necessity decisions. It also reinforces the nationwide importance of subjective scienter after Schutte. FCA plaintiffs must connect alleged billing defects to what the defendant knew, suspected, or deliberately avoided knowing when claims were submitted.

Clinical laboratories should nevertheless avoid treating OMNI as a universal defense. Different facts, regulations, coverage policies, marketing conduct, or internal communications could defeat reliance on physician orders. The decision offers clarity, not invisibility.

Experience-Based Scenario: Turning the OMNI Ruling Into Daily Practice

The following composite scenario illustrates how the decision can guide a real-world compliance response without pretending that every laboratory dispute arrives wearing a convenient name tag.

Imagine a regional laboratory launches a molecular UTI panel containing 18 pathogen targets. The clinical team believes the panel can produce faster and more detailed results than conventional culture. Sales representatives begin presenting it to primary-care and long-term-care providers, and ordering volume climbs quickly.

Three months later, the compliance dashboard identifies an odd pattern. Several practices order the full panel for nearly every patient, regardless of diagnosis, symptoms, treatment history, or prior test results. One physician emails customer service and says she thought she was ordering a basic UTI test, not 18 separately billed targets.

A weak response would be: “There is a signed order, so the First Circuit says we are fine.” That approach misunderstands the ruling. The provider’s message is countervailing evidence suggesting that the order may not reflect an informed medical-necessity determination. The laboratory now has a reason to investigate.

A stronger compliance team pauses outreach involving the disputed form, preserves the relevant documents, and reviews the electronic ordering workflow. It discovers that the full panel was automatically selected when users clicked “molecular UTI.” Providers could deselect individual targets, but the option appeared behind a small menu that few noticed. Sales representatives had also described the panel as the laboratory’s “standard UTI test,” without explaining its breadth.

The laboratory then interviews sales personnel, reviews training materials, compares claims with clinical documentation, and contacts affected practices. It redesigns the requisition so that providers must affirmatively select either a focused test or the broader panel. It adds plain-language descriptions, requires documented approval before employees alter selections, retrains the sales force, and audits previously paid claims for possible overpayments.

This experience reveals the practical value of OMNI. A legitimate provider order can be strong evidence of medical necessity when the laboratory has not corrupted the ordering process. But when the laboratory’s form, marketing, or workflow influences the order in a misleading way, the signature may no longer provide dependable protection.

Another recurring lesson concerns internal communications. Suppose a billing manager writes, “The contractor keeps denying these panels, but keep submitting them until someone tells us to stop.” That sentence creates a very different scienter record from an email stating, “Coverage guidance is unclear; please obtain clinical and legal review before the next billing cycle.” Both messages acknowledge uncertainty, but only one demonstrates an organized effort to resolve it.

Good compliance experience is therefore built around disciplined curiosity. Teams should investigate unusual data, encourage employees to raise concerns, document why tests are billed, and close the loop when guidance changes. The objective is not to make laboratories diagnose patients. It is to ensure that physician reliance remains genuine, informed, and untainted by the laboratory’s own conduct.

Conclusion

The First Circuit gave clinical laboratories an important and practical FCA rule: a laboratory may generally rely on a physician’s test order as evidence of medical necessity. An FCA plaintiff seeking to proceed must offer evidence showing why that reliance was dishonest, reckless, deliberately ignorant, or otherwise unjustified.

At the same time, the decision leaves the laboratory’s core compliance obligations firmly in place. Accurate claims, neutral requisition forms, truthful marketing, documented coverage analysis, responsible panel design, and prompt investigation of red flags remain essential.

The best summary is simple. Laboratories are not required to become substitute physicians, but neither may they manufacture the medical judgment on which their claims depend.

Note: This article provides general information and does not constitute legal advice. Organizations should consult qualified counsel regarding specific billing, reimbursement, False Claims Act, or laboratory compliance questions.